Bicara Therapeutics (NASDAQ:BCAX) Hits New 1-Year High – Here’s What Happened

Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) reached a new 52-week high during trading on Monday . The stock traded as high as $24.49 and last traded at $23.88, with a volume of 70774 shares changing hands. The stock had previously closed at $23.23.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the stock. Guggenheim began coverage on shares of Bicara Therapeutics in a research report on Monday, May 11th. They set a “buy” rating and a $42.00 price objective on the stock. The Goldman Sachs Group upped their target price on shares of Bicara Therapeutics from $16.00 to $18.00 and gave the company a “neutral” rating in a report on Tuesday, May 12th. HC Wainwright increased their target price on shares of Bicara Therapeutics from $40.00 to $42.00 and gave the stock a “buy” rating in a research note on Tuesday, March 31st. Citizens Jmp reissued a “market outperform” rating and set a $31.00 price target on shares of Bicara Therapeutics in a report on Tuesday, March 31st. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Bicara Therapeutics in a report on Wednesday, April 8th. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $30.27.

Bicara Therapeutics Stock Up 1.8%

The company has a market capitalization of $1.64 billion, a PE ratio of -8.99 and a beta of -0.53. The stock’s fifty day simple moving average is $21.95 and its 200-day simple moving average is $19.18.

Bicara Therapeutics (NASDAQ:BCAX) last announced its quarterly earnings results on Monday, May 11th. The company reported ($0.93) EPS for the quarter, missing the consensus estimate of ($0.72) by ($0.21). Analysts expect that Bicara Therapeutics Inc. will post -3.48 EPS for the current year.

Insider Transactions at Bicara Therapeutics

In other Bicara Therapeutics news, CFO Ivan Hyep sold 9,200 shares of the business’s stock in a transaction on Thursday, May 21st. The stock was sold at an average price of $20.42, for a total transaction of $187,864.00. Following the sale, the chief financial officer directly owned 145,355 shares in the company, valued at approximately $2,968,149.10. The trade was a 5.95% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Claire Mazumdar sold 15,000 shares of the company’s stock in a transaction on Monday, April 20th. The shares were sold at an average price of $23.61, for a total value of $354,150.00. Following the completion of the sale, the chief executive officer directly owned 362,152 shares in the company, valued at $8,550,408.72. This trade represents a 3.98% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 63,900 shares of company stock valued at $1,420,704. Company insiders own 13.80% of the company’s stock.

Hedge Funds Weigh In On Bicara Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Legal & General Group Plc grew its position in shares of Bicara Therapeutics by 64.1% in the second quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock valued at $29,000 after purchasing an additional 1,233 shares during the last quarter. Tower Research Capital LLC TRC raised its position in shares of Bicara Therapeutics by 419.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,788 shares of the company’s stock worth $44,000 after purchasing an additional 3,866 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Bicara Therapeutics during the 4th quarter worth approximately $45,000. Larson Financial Group LLC lifted its stake in Bicara Therapeutics by 1,015.5% in the 3rd quarter. Larson Financial Group LLC now owns 3,949 shares of the company’s stock valued at $62,000 after buying an additional 3,595 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd lifted its stake in Bicara Therapeutics by 385.3% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 5,775 shares of the company’s stock valued at $97,000 after buying an additional 4,585 shares in the last quarter.

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.